8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Amgen reports Q2 revenue growth and raises free cash flow to $3.5 billion
Filed with the SEC on · Summarized by InvestorsBot
Amgen reported second-quarter 2026 revenue of $10.1 billion, up 10% from a year earlier, while GAAP diluted EPS rose to $4.37 from $2.65 and non-GAAP diluted EPS increased to $6.29 from $6.02. Free cash flow reached $3.5 billion versus $1.9 billion in the second quarter of 2025; Amgen maintained 2026 guidance for revenue of $38.2 billion to $39.4 billion and non-GAAP EPS of $22.30 to $23.50, while noting pressure on Prolia and XGEVA from biosimilars and discontinuing future development of AMG 513.